Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis Supplemental Video

For patients randomized to IXE Q2W, the median time to a 1-point or greater improvement and a 2-point or greater improvement in the PatGA from baseline was 5.0 and 10.0 days, respectively. The median time to a 1-point or greater improvement and a 2-point or greater improvement from baseline in PatGA was 6.0 and 13.5 days for patients randomized to IXE Q4W, respectively. By Weeks 2 and 4, all patients achieved at least 50- or 75-percent PASI improvement from baseline, respectively (Figure 1). Of 11 patients with a baseline Itch NRS score of at least 4 (1 patient had a baseline Itch NRS score of 1), at least half (Q2W: 3 patients, 50.0%; Q4W: 3 patients, 60.0%) achieved at least a 4-point Itch NRS improvement from baseline by Day 14 (Figure 1C). Patient photographs demonstrated visible improvement in disease within one week of treatment (Supplemental Video). Click here to access article.